SUMM.L Regulatory News (SUMM)

2 Jul 2007 09:00

VASTox plc02 July 2007 VASTox plc ("VASTox" or "the Company") VASTOX TO HOST R&D DAY ON 24 JULY 2007 IN LONDON Oxford, UK, 2 July 2007 - VASTox plc (AIM: VOX), a leading UK biotechnologycompany, is planning to hold an R&D day in London on 24 July 2007 for investors,analysts and members of the press. The programme of presentations will covervarious aspects of VASTox's enhanced drug pipeline, its clinical programmes andthe potential of its zebrafish screening platform, following its recentacquisitions of MNL Pharma, Daniolabs and Dextra Laboratories. In addition, Professor Francesco Muntoni, Professor of Paediatric Neurology atthe Hammersmith Hospital, and Dr Paul Goldsmith, a consultant neurologist atAddenbrookes Hospital, will provide clinical perspectives on the areas ofneuromuscular diseases and Parkinson's disease, respectively. The event will be held at the offices of Huntsworth Health plc, 8th Floor, 26Finsbury Square, London EC2A 1SF, beginning at 10.00hrs and followed by a buffetlunch. For further information and to register interest in attending, please contactMark Swallow, Valerie Auffray or Janine Hagan at Citigate Dewe Rogerson on +44(0)207 282 1068 or email janine.hagan@citigaterdr.co.uk A preliminary programme is outlined below: Dr Richard Storer, Overview of drug portfolio & twin technology platformsChief Scientific Officer, VASTox Dr Paul Goldsmith Parkinson's Disease: Sialorrhoea and Seborrhoea. A clinicians perspectiveConsultant Neurologist, AddenbrookesHospitalDr Nigel Blackburn The clinical development plan for the Parkinson's programmesDirector of Clinical Development, VASTox Prof. Francesco Muntoni Neuromuscular diseases: a clinical focusPaediatric Neurologist, HammersmithHospital and Imperial College Dr Jon Tinsley VASTox neuromuscular disease programmes: a focus on Duchenne muscular dustrophyDirector of Therapeutic Programmes,VASTox Dr Richard Storer A Broad and diverse pipeline: VOX14400, Glaucoma and TB Chief Scientific Officer, VASToxDr Alan Roach Zebrafish: the in vivo advantage Director of Biology, VASToxProf Robert Nash Carbohydrates: an emerging technology for the development of new drugsDirector of Research, VASTox(Aberystwyth) - ends - For more information please contact: VASTox Steven Lee, PhD, Chief Executive Officer Tel: +44 (0)1235 443951 Darren Millington, ACMA, Chief Financial Officer Citigate Dewe Rogerson Mark Swallow / David Dible / Valerie Auffray Tel: +44 (0)207 638 9571 Evolution Securities Tim Worlledge / Bobbie Hilliam / Neil Elliot Tel: +44 (0)207 071 4300 About VASTox plc VASTox is a leading UK biotechnology company that discovers and developsproprietary new drugs. The Company's internal drug development programmes areunderpinned by its advanced chemistry and drug screening (chemical genomics)technology platforms, which it also provides on a collaborative orfee-for-service basis to the pharmaceutical industry. VASTox has a broad range of drug discovery programmes in the clinical,pre-clinical and discovery stages of development, which target serious diseaseswith a high unmet medical need. These therapeutic areas include neuro-disorders(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,oncology and regenerative medicines. VASTox's in-house drug development capabilities combine world-class expertise inboth medicinal and carbohydrate chemistry with high-volume, high-contentscreening using its proprietary zebrafish and fruitfly technologies (chemicalgenomics). These whole organism screens have the potential to dramaticallydecrease the time and cost of drug discovery and development by delivering datathat are highly predictive of the efficacy and toxicity of potential drugcompounds in humans. The company listed on the AIM market of the London Stock Exchange in October2004 - symbol: VOX Further information about the company is available at www.vastox.com This document contains "forward-looking statements" within the meaning of theU.S. Private Securities Litigation Reform Act of 1995. Forward-lookingstatements can be identified by words such as "anticipates", "intends", "plans","seeks", "believes", "estimates", "expects" and similar references to futureperiods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations andassumptions regarding our business, the economy and other future conditions.Because forward-looking statements relate to the future, by their nature, theyare subject to inherent uncertainties, risks and changes in circumstances thatare difficult to predict. The Company's actual results may differ materiallyfrom those contemplated by the forward-looking statements. The Company cautionsyou therefore that you should not rely on any of these forward-lookingstatements as statements of historical fact or as guarantees or assurances offuture performance. Important factors that could cause actual results to differmaterially from those in the forward-looking statements and regional, national,global political, economic, business, competitive, market and regulatoryconditions. This information is provided by RNS The company news service from the London Stock Exchange